Development and Internal Validation of a Clinical–Infectious Prediction Model Incorporating the Serum Pepsinogen I/II Ratio to Identify Histologically Confirmed Gastric Atrophy
DOI:
https://doi.org/10.67076/cmj.2026.v4n2.02Keywords:
gastric atrophy, pepsinogen I/II ratio, Helicobacter pylori, Epstein–Barr virus, prediction model, gastric cancer prevention, internal validationAbstract
Background: Histologically confirmed gastric atrophy is a key precursor lesion in the intestinal pathway of gastric carcinogenesis. Serum pepsinogen I/II ratio (PGR) is a biologically plausible non-invasive marker of oxyntic gland loss, but its diagnostic performance varies across populations, assays, and clinical settings. Contemporary risk stratification increasingly favors multivariable prediction models over isolated biomarkers.
Objective: To evaluate the association between serum PGR and histologically confirmed gastric atrophy and to quantify the incremental contribution of PGR to a prespecified clinical–infectious prediction model.
Methods: This prospective observational study enrolled 120 consecutive adults undergoing diagnostic upper gastrointestinal endoscopy at a tertiary referral center between January 2024 and February 2026. Participants underwent fasting serum pepsinogen I and II measurement, polymerase-chain-reaction testing for Helicobacter pylori, assessment of Epstein–Barr virus (EBV) status, and histopathological examination of gastric biopsy specimens. Logistic regression was used to estimate associations with gastric atrophy. Discrimination was quantified using the area under the receiver operating characteristic curve (AUC), overall accuracy using the Brier score, and internal validity using bootstrap resampling.
Results: Histologically confirmed gastric atrophy was present in 32 of 120 patients (26.7%). Median PGR was lower in patients with gastric atrophy than in those with intestinal metaplasia or epithelial dysplasia (4.87 vs 6.53 and 6.27, respectively; Kruskal–Wallis P=0.0076). After adjustment for age, sex, H. pylori status, and EBV status, PGR remained independently associated with gastric atrophy (adjusted odds ratio [OR] 0.771 per unit increase; 95% confidence interval [CI] 0.619–0.960; P=0.020). The apparent AUC increased from 0.644 for the clinical–infectious model to 0.732 after addition of PGR; the bootstrap optimism-corrected AUC was 0.669. The Brier score was 0.171. At a cohort-derived threshold of PGR ≤5.56, sensitivity was 81.3%, specificity 68.2%, positive predictive value 48.1%, and negative predictive value 90.9%.
Conclusions: Lower serum PGR was independently associated with histologically confirmed gastric atrophy and improved apparent discrimination when added to a clinical–infectious model. However, the optimism-corrected performance was only moderate, and the threshold was derived in a small single-center cohort. PGR should therefore be considered an adjunctive triage biomarker rather than a replacement for protocol-based endoscopy and histopathology. External validation and clinical-impact evaluation are required before implementation.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–249. DOI: https://doi.org/10.3322/caac.21660
Morgan E, Arnold M, Camargo MC, et al. The current and future incidence and mortality of gastric cancer in 185 countries, 2020–40: a population-based modelling study. EClinicalMedicine. 2022;47:101404. DOI: https://doi.org/10.1016/j.eclinm.2022.101404
Thrift AP, El-Serag HB. Burden of gastric cancer. Clin Gastroenterol Hepatol. 2020;18:534–542. DOI: https://doi.org/10.1016/j.cgh.2019.07.045
Correa P. Human gastric carcinogenesis: a multistep and multifactorial process. Cancer Res. 1992;52:6735–6740.
Rugge M, Genta RM, Di Mario F, et al. Gastric cancer as preventable disease. Clin Gastroenterol Hepatol. 2017;15:1833–1843. DOI: https://doi.org/10.1016/j.cgh.2017.05.023
Dinis-Ribeiro M, et al. Management of epithelial precancerous conditions and early neoplasia of the stomach (MAPS III): ESGE, EHMSG and ESP Guideline update 2025. Endoscopy. 2025;57:504–554. doi:10.1055/a-2529-5025. DOI: https://doi.org/10.1055/a-2529-5025
Malfertheiner P, Megraud F, Rokkas T, et al. Management of Helicobacter pylori infection: the Maastricht VI/Florence Consensus Report. Gut. 2022;71:1724–1762. DOI: https://doi.org/10.1136/gutjnl-2022-327745
Shah SC, Piazuelo MB, Kuipers EJ, Li D. AGA Clinical Practice Update on the diagnosis and management of atrophic gastritis: Expert Review. Gastroenterology. 2021;161:1325–1332.e7. DOI: https://doi.org/10.1053/j.gastro.2021.06.078
Shah SC, et al. AGA Clinical Practice Update on screening and surveillance in individuals at increased risk for gastric cancer in the United States: Expert Review. Gastroenterology. 2025. DOI: https://doi.org/10.1053/j.gastro.2024.11.001
American College of Gastroenterology. ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions. Am J Gastroenterol. 2025.
Gupta S, Li D, El Serag HB, et al. AGA Clinical Practice Guidelines on management of gastric intestinal metaplasia. Gastroenterology. 2020;158:693–702. DOI: https://doi.org/10.1053/j.gastro.2019.12.003
Rugge M, Meggio A, Pravadelli C, et al. Gastritis staging in clinical practice: the OLGA staging system. Gut. 2007;56:631–636. DOI: https://doi.org/10.1136/gut.2006.106666
Rugge M, Correa P, Di Mario F, et al. OLGA staging for gastritis: a tutorial. Dig Liver Dis. 2008;40:650–658. DOI: https://doi.org/10.1016/j.dld.2008.02.030
Capelle LG, de Vries AC, Haringsma J, et al. The staging of gastritis with the OLGA system by using intestinal metaplasia as an accurate alternative for atrophic gastritis. Gastrointest Endosc. 2010;71:1150–1158. DOI: https://doi.org/10.1016/j.gie.2009.12.029
Benites-Goñi H, et al. OLGA and OLGIM staging systems on the risk assessment of gastric cancer: a systematic review and meta-analysis of prospective cohorts. Therap Adv Gastroenterol. 2025. DOI: https://doi.org/10.1177/17562848251325461
Na YS, et al. Risk assessment of metachronous gastric cancer using OLGA and OLGIM staging systems. 2023; PMID:36609936.
In H, et al. Serum pepsinogen as a biomarker for gastric cancer in the United States. 2022; PMCID:PMC9268394.
Zagari RM, Rabitti S, Greenwood DC, et al. Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti-Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis. Aliment Pharmacol Ther. 2017;46:657–667. DOI: https://doi.org/10.1111/apt.14248
Oh A, et al. Cost-effectiveness of serum pepsinogen as a gastric cancer screening biomarker. 2024; PMCID:PMC11762188.
Tan HJ, et al. Postprandial gastrin-17 level is a useful dynamic marker for endoscopic atrophic gastritis. 2024; PMCID:PMC11586718. DOI: https://doi.org/10.4253/wjge.v16.i11.623
Zhang T, et al. The potential value of serum pepsinogen and gastrin-17 for evaluating chronic atrophic gastritis severity. 2025; PMCID:PMC12135244.
Han X, et al. Value of serum pepsinogen ratio screening for early gastric neoplasia. 2024; PMCID:PMC11650226.
Choi Y, et al. Role of serum pepsinogen tests in detection of gastric mucosal disease and neoplasia. 2025; PMCID:PMC12616145.
Lim SH, et al. Assessing serum pepsinogen and Helicobacter pylori biomarkers for gastric cancer risk. Cancers (Basel). 2025;17:955. DOI: https://doi.org/10.3390/cancers17060955
Collins GS, Moons KGM, Dhiman P, et al. TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods. BMJ. 2024;385:e078378.
Wolff RF, Moons KGM, Riley RD, et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Ann Intern Med. 2019;170:51–58. DOI: https://doi.org/10.7326/M18-1376
Moons KGM, Wolff RF, Riley RD, et al. PROBAST: explanation and elaboration. Ann Intern Med. 2019;170:W1–W33. DOI: https://doi.org/10.7326/M18-1377
Riley RD, Ensor J, Snell KIE, et al. Calculating the sample size required for developing a clinical prediction model. BMJ. 2020;368:m441. DOI: https://doi.org/10.1136/bmj.m441
Riley RD, Debray TPA, Collins GS, et al. Minimum sample size for external validation of a clinical prediction model with a binary outcome. Stat Med. 2021;40:4230–4251. DOI: https://doi.org/10.1002/sim.9025
Van Calster B, McLernon DJ, van Smeden M, Wynants L, Steyerberg EW. Calibration: the Achilles heel of predictive analytics. BMC Med. 2019;17:230. DOI: https://doi.org/10.1186/s12916-019-1466-7
Steyerberg EW. Clinical Prediction Models. 2nd ed. Cham: Springer; 2019. DOI: https://doi.org/10.1007/978-3-030-16399-0
von Elm E, Altman DG, Egger M, et al. The STROBE statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457. DOI: https://doi.org/10.1016/S0140-6736(07)61602-X
Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis: the Updated Sydney System. Am J Surg Pathol. 1996;20:1161–1181. DOI: https://doi.org/10.1097/00000478-199610000-00001
Areia M, et al. Performance measures for upper gastrointestinal endoscopy: ESGE quality improvement initiative update. Endoscopy. 2025; PMID:40934951.
Harrell FE Jr. Regression Modeling Strategies. 2nd ed. Cham: Springer; 2015. DOI: https://doi.org/10.1007/978-3-319-19425-7
Steyerberg EW, Harrell FE Jr. Prediction models need appropriate internal, internal–external, and external validation. J Clin Epidemiol. 2016;69:245–247. DOI: https://doi.org/10.1016/j.jclinepi.2015.04.005
Vickers AJ, van Calster B, Steyerberg EW. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res. 2019;3:18. DOI: https://doi.org/10.1186/s41512-019-0064-7
Li J, et al. Chronic atrophic gastritis and risk of incident upper gastrointestinal malignancy: a systematic review and meta-analysis. 2024; PMCID:PMC11075312. DOI: https://doi.org/10.1186/s12967-023-04736-w
Isajevs S, et al. High-risk individuals for gastric cancer may be missed by incomplete biopsy and staging strategies. 2021; PMCID:PMC8740520.
Wu M, et al. Helicobacter pylori infection combined with OLGA and OLGIM staging for gastric cancer risk assessment. 2022; PMID:36475275.
Coelho MCF, et al. Helicobacter pylori chronic gastritis and OLGA/OLGIM risk stratification. 2021; PMID:33909795.
Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. MAPS II: management of epithelial precancerous conditions and lesions in the stomach. Endoscopy. 2019;51:365–388. DOI: https://doi.org/10.1055/a-0859-1883
Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64:1353–1367. DOI: https://doi.org/10.1136/gutjnl-2015-309252
Choi IJ, Kim CG, Lee JY, et al. Family history of gastric cancer and Helicobacter pylori treatment. N Engl J Med. 2020;382:427–436. DOI: https://doi.org/10.1056/NEJMoa1909666
Ford AC, Yuan Y, Forman D, Hunt R, Moayyedi P. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2020;7:CD005583. DOI: https://doi.org/10.1002/14651858.CD005583.pub3
Liou JM, Malfertheiner P, Lee YC, et al. Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus. Gut. 2020;69:2093–2112. DOI: https://doi.org/10.1136/gutjnl-2020-322368
Zhao K, et al. Epstein–Barr virus is associated with gastric cancer precursor lesions. 2022; PMID:35693736; PMCID:PMC9149642.
Dursun N, et al. Epstein–Barr virus infection in patients with chronic gastritis without Helicobacter pylori infection. 2020; PMCID:PMC7197925. DOI: https://doi.org/10.5152/tjg.2020.18850
Corallo S, et al. Unlocking the potential of Epstein–Barr virus in gastric carcinogenesis. Pathogens. 2024;13:728. DOI: https://doi.org/10.3390/pathogens13090728
Qiao X, et al. Causal association between Epstein–Barr virus and gastritis, gastric ulcer and gastric cancer: a Mendelian randomization study. Sci Rep. 2025. DOI: https://doi.org/10.1038/s41598-025-08555-5
Rugge M, et al. RE.GA.IN.: the Real-world Gastritis Initiative—updating the clinical approach to gastritis. Gut. 2024;73:994–1006. DOI: https://doi.org/10.1136/gutjnl-2023-331164
Kim GH, Liang PS, Bang SJ, Hwang JH. Screening and surveillance for gastric cancer in the United States: is it needed? Gastrointest Endosc. 2016;84:18–28. DOI: https://doi.org/10.1016/j.gie.2016.02.028
Shah SC, McKinley M, Gupta S, Peek RM Jr, Martinez ME, Gomez SL. Population-based analysis of differences in gastric cancer incidence among races and ethnicities in individuals age 50 years and older. Gastroenterology. 2020;159:1705–1714.e2. DOI: https://doi.org/10.1053/j.gastro.2020.07.049
Banks M, Graham D, Jansen M, et al. British Society of Gastroenterology guidelines on diagnosis and management of patients at risk of gastric adenocarcinoma. Gut. 2019;68:1545–1575. DOI: https://doi.org/10.1136/gutjnl-2018-318126
Pimentel-Nunes P, et al. Endoscopic diagnosis and management of gastric premalignant and early neoplastic conditions: contemporary evidence and implementation. 2023.
Wynants L, Van Calster B, Collins GS, et al. Prediction models for diagnosis and prognosis of COVID-19: systematic review and critical appraisal. BMJ. 2020;369:m1328. DOI: https://doi.org/10.1136/bmj.m1328
Debray TPA, Damen JAAG, Snell KIE, et al. A guide to systematic review and meta-analysis of prediction model performance. BMJ. 2017;356:i6460. DOI: https://doi.org/10.1136/bmj.i6460
Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD). Ann Intern Med. 2015;162:55–63. DOI: https://doi.org/10.7326/M14-0697
Steyerberg EW, Vickers AJ, Cook NR, et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128–138. DOI: https://doi.org/10.1097/EDE.0b013e3181c30fb2
DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated ROC curves. Biometrics. 1988;44:837–845. DOI: https://doi.org/10.2307/2531595
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Azerbaijan Gastroenterology and Invasive Endoscopy Society
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
